More intelligence articles

On our best behaviour

Why driving behaviour change is the next big focus for pharma companies in chronic diseases

The science of the deal

Business development is more like child-raising than you might think

Exploring the potential of eosinophils

GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils

Eliminating pharmaceutical rebates, is this déjà vu?

By Andrew Parece and Matthew Majewski

COVID-19 – a catalyst for technology adoption in clinical trials

As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good

How will COVID-19 affect uptake of vaccinations against other diseases?

Will COVID-19 help or hinder the quest to increase uptake of other vaccinations?

Bombarded with information – the challenge of crowded digital channels

Chris Ross explores the pursuit of communications excellence in a world of noise

Multilingual remote conferencing and interpreting platforms in the era of COVID-19

Turning the pharmaceutical language behind vaccine development into engaging, accessible content

The importance of pharma intelligence in setting brand strategy

Looking at the different approaches that can be leveraged to assess the competition

Leadership and talent

Looking at the key objectives of running leadership programmes

Switzerland: a life sciences hub

Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country

Taking a holistic approach to patient care

The importance of recognising each patient as an individual

Surviving cancer: a new era for patients

Now more than ever, a shift in perspective is needed

Could formulary intelligence be your brand differentiator?

Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch

How COVID-19 is accelerating the threat of antimicrobial resistance

Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19